Tia Ivory
Family · Kilgore, TXNPI 1689176885
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,044 and has fallen 64.5% since, to $370 in 2024.
Across 155 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$420
- Novo Nordisk$420
- Bayer$395
- Teva Pharmaceuticals USA, Inc.$267
- Lilly USA, LLC$179
- Pfizer$160
- plus $687 from 15 others
What the payments were for
- Food & beverage$2,529100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $420 |
| Novo Nordisk | 43 | $420 |
| Bayer | 26 | $395 |
| Teva Pharmaceuticals USA, Inc. | 5 | $267 |
| Lilly USA, LLC | 12 | $179 |
| Pfizer | 5 | $160 |
| Kowa Pharmaceuticals America, Inc. | 8 | $125 |
| AstraZeneca | 5 | $102 |
| Merck | 6 | $99 |
| Evoke Pharma, Inc. | 3 | $89 |
| Amarin Pharma, Inc. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Amgen | 2 | $24 |
| Gilead | 1 | $22 |
| Organon | 1 | $21 |
| Abbott | 1 | $18 |
| GSK | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$109
- Austedo XR$109
How this compares
$2,529 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $20,011 |
| Benztropine Mesylate | 15 | $328 |
| Amlodipine Besylate | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Other family in Kilgore
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.